Drug Type Small molecule drug |
Synonyms Atorvastatin/torcetrapib, Torcetrapib/atorvastatin |
Action inhibitors, stimulants |
Mechanism CETP inhibitors(Cholesteryl ester transfer protein inhibitors), HDL-cholesterol stimulants, HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC33H35CaFN2O5 |
InChIKeyBWFCZHDTTAYGNN-CNZCJKERSA-N |
CAS Registry134523-03-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Coronary Artery Disease | Phase 3 | Belgium | 01 Oct 2003 | |
Coronary Artery Disease | Phase 3 | Netherlands | 01 Oct 2003 | |
Coronary Artery Disease | Phase 3 | Spain | 01 Oct 2003 | |
Coronary Artery Disease | Phase 3 | Belgium | 01 Oct 2003 | |
Coronary Artery Disease | Phase 3 | Poland | 01 Oct 2003 | |
Coronary Artery Disease | Phase 3 | Netherlands | 01 Oct 2003 | |
Coronary Artery Disease | Phase 3 | Spain | 01 Oct 2003 | |
Coronary Artery Disease | Phase 3 | Poland | 01 Oct 2003 | |
Hyperlipidemias | Phase 3 | Spain | 01 Oct 2003 | |
Hyperlipidemias | Phase 3 | Poland | 01 Oct 2003 |